This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Watanabe, S Articles by Itoyama, Y Search for Related Content PubMed PubMed Citation Articles by Watanabe, S Articles by Itoyama, Y Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB METHYLPREDNISOLONE Social Bookmarking                   What's this?

Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica

I Nakashima

T Misu

I Miyazawa

Y Shiga

Department of Neurology, Tohoku University School of Medicine, Sendai, Japan

K Füjihara

Department of Neurology, Tohoku University School of Medicine, Sendai, Japan; Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryomachi, Aobaku, Sendai 980-8574, Japan; fujikazu{at}em.neurol.med.tohoku.ac.jp

Y Itoyama

Department of Neurology, Tohoku University School of Medicine, Sendai, Japan

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system (CNS) with a poor prognosis in terms of the optic-spinal function. Recently, a serum autoantibody (NMO-IgG) binding to the blood–brain barrier region was detected exclusively in patients with NMO and its high risk group. We treated six NMO-IgG-positive patients (all female; age 21–67 years old, median 41; three with optic neuritis and three with myelitis) who were unresponsive to high-dose intravenous methylprednisolone (HIMP), with plasma exchange (PE) (three to five exchanges, 2–3 L each). Three of the patients(one with optic neuritis and two with myelitis) showed definite functional improvement following PE. The clinical improvement started to appear after one or two exchanges, while there was little or no improvement in the other three patients. Such quick clinical responses to PE suggest a pathogenetic role of humoral immune factors in NMO, although delayed responses to the corticosteroid therapy might have contributed to the therapeutic efficacy, in part. Further clinical and in vitro studies are needed to determine whether the removal of NMO-IgG is directly relevant to the therapeutic efficacy. PE may hasten the functional recovery from corticosteroid-resistant relapses in some NMO-IgG-positive patients with NMO.

Key Words: aquaporin-4 • Devic's disease • neuromyelitis optica • NMO-IgG • plasma exchange • therapy

Multiple Sclerosis, Vol. 13, No. 1, 128-132 (2007)
DOI: 10.1177/1352458506071174


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S Viegas, A Weir, M Esiri, W Kuker, P Waters, M I Leite, A Vincent, and J Palace Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica J. Neurol. Neurosurg. Psychiatry, June 1, 2009; 80(6): 679 - 682. [Abstract] [Full Text] [PDF]

				M Bonnan, R Valentino, S Olindo, H Mehdaoui, D Smadja, and P Cabre Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder Multiple Sclerosis, April 1, 2009; 15(4): 487 - 492. [Abstract] [PDF]

				T. Vincent, P. Saikali, R. Cayrol, A. D. Roth, A. Bar-Or, A. Prat, and J. P. Antel Functional Consequences of Neuromyelitis Optica-IgG Astrocyte Interactions on Blood-Brain Barrier Permeability and Granulocyte Recruitment J. Immunol., October 15, 2008; 181(8): 5730 - 5737. [Abstract] [Full Text] [PDF]

				A. McKeon, V. A. Lennon, T. Lotze, S. Tenenbaum, J. M. Ness, M. Rensel, N. L. Kuntz, J. P. Fryer, H. Homburger, J. Hunter, et al. CNS aquaporin-4 autoimmunity in children Neurology, July 8, 2008; 71(2): 93 - 100. [Abstract] [Full Text] [PDF]

				T. Okamoto, M. Ogawa, Youwei Lin, M. Murata, S. Miyake, and T. Yamamura Review: Treatment of neuromyelitis optica: Current debate Therapeutic Advances in Neurological Disorders, July 1, 2008; 1(1): 43 - 52. [Abstract] [PDF]

				E Moreh, I Gartsman, D Karussis, D Rund, N Hiller, and Z Meiner Seronegative neuromyelitis optica: improvement following lymphocytapheresis treatment Multiple Sclerosis, July 1, 2008; 14(6): 860 - 861. [PDF]